Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance PR Newswire ATLANTA , April 17, 2023 /PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U...
Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks PR Newswire Patients treated with investigational bimekizumab, an IL-17A and IL-17F inhibitor, achieved statistically significant and clinically meaningf...
UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa PR Newswire Phase 3 data on investigational bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa ...
2023-03-06 17:07:59 ET Summary Immunovant's lead drug, batoclimab, is one of many FcRn antagonists, either approved or in development, for the treatment of autoimmune diseases, including myasthenia gravis (MG). In batoclimab clinical trials by Immunovant, safety concerns emerged w...
Summary argenx pre-announced strong Q4 net sales of Vyvgart in early January. The PDUFA date for subcutaneous efgartigimod was pushed back by three months, which means the $98 million Priority Review voucher went to waste. Getting subcutaneous efgartigimod to market is important as ...
Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis PR Newswire Publication of 24-week results from the BE MOBILE 1 and BE MOBILE 2 studies, evaluating bimekizumab, an IL-17A and IL-17F inhibitor, across the full s...
Summary Immunovant is developing a similar drug to argenx, but at 10% of argenx’s valuation, offering a good option value and a hedge against owning argenx. Immunovant has a new generation anti-FcRn IMVT-1402, and recent pre-clinical data showed that it does not impact albumin le...
UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review PR Newswire Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment...
UCB ( OTCPK:UCBJY ) ( OTCPK:UCBJF ) said its medicine bimekizumab met the main goal of two phase three studies to treat a skin condition called hidradenitis suppurativa The studies dubbed BE HEARD I and BE HEARD II, evaluated bimekizumab in adults with moderate to s...
UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa PR Newswire Top-line results show that the two Phase 3 studies, BE HEARD I and BE HEARD II, met their primary and key secondary endpoints with statistical significance and consistent clinical re...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 PR Newswire Patients with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS) treated ...